Primary record
4 inverted exclamation mark -[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2 inverted exclamation mark -(ethoxymethyl)-[1,1 inverted exclamation mark -biphenyl]-2-sulfonamide
- 库存
- 6,319 克
- 纯度
- 99.0 %
- CAS
- 254740-64-2
化合物标识与属性
- CAS
- 254740-64-2
- PubChem CID
- 10257882
- SMILES
- CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
- Canonical SMILES
- CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
名称与同义词
- sparsentan
- Sparsentan (RE-021)
- esparsentan
- retrophin
- sparsentanum
- FILSPARI
- 254740-64-2
- Spashentan
- Sparsentan [USAN]
- Filspari (TN)
- RE-021
- DARA
- RefChem:56752
- PS433540
- SPARSENTAN [INN]
- 9242RO5URM
- UNII-9242RO5URM
- D05PYP
- D0YS1U
- CHEMBL539423
- SPARSENTAN [WHO-DD]
- RE 201
- Sparsentan(PS433540)?
- C32H40N4O5S
- PS-433540
- SCHEMBL535109
- Sparsentan (JAN/USAN/INN)
- GTPL8448
- orb1301859
- SCHEMBL29706489
- CHEBI:229526
- MFCD16628036
- compound 7 [PMID 15634011]
- GLXC-15418
- RE021
- BMS-346567
- AMY38147
- BCP23969
- EX-A3048
- BDBM50175523
- s6665
- PS 33540
- AKOS040758741
- CS-7947
- DB12548
- SB16876
- CID10257882
- PS-433540;RE-021;DARA
- AC-35179
- CID 10257882
- DA-67132
- HY-17621
- MS-30544
- SY335644
- PS 433540
- NS00070334
- Sparsentan (PS-433540,RE-021,DARA)
- 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
- J2.228.316B
- D11776
- F77045
- 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
- A858308
- L023324
- Q27088845
- B0084-475592
- B1370-200412
- (1,1'-Biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
- DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors)
- 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
- [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
- 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
- 4 inverted exclamation mark -[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2 inverted exclamation mark -(ethoxymethyl)-[1,1 inverted exclamation mark -biphenyl]-2-sulfonamide
- 4''''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide
- 4''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide
- 4'-((2-BUTYL-4-OXO-1,3-DIAZASPIRO(4.4)NON-1-EN-3-YL)METHYI)-N-(4,5- DIMETHYLISOXAZOL-3-YL)-2'-(ETHOXYMETHYL)BIPHENYL-2-SULFONAMIDE
- 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-(1,1'-biphenyl)-2-sulfonamide
- 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide
- 4'-({2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl}methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
- 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[biphenyl]-2-sulfonamide
- 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
- 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide
- N-(4,5-Dimethylisoxazole-3-yl)-2 -(ethoxymethyl)-4 -[(2-butyl-4-oxo-1,3-diazaspiro[4.4]nona-1-ene-3-yl)methyl]biphenyl-2-sulfonamide